Healthcare

Patient & Disease Intelligence

Our patient panels provide deep ethnographic and clinical insights into the patient journey. We specialize in gathering real-world evidence from diverse patient groups to help pharmaceutical companies understand life-impact beyond the diagnosis.

This data includes:

  • Rare Disease Access: Connection with patients and caregivers dealing with orphan diseases.
  • Chronic Condition Tracking: Long-term data on patients with Diabetes, Hypertension, and Auto-immune disorders.
  • Patient Journey Mapping: Insights into the time from first symptoms to diagnosis and treatment.
  • Treatment Adherence: Data on why patients continue or discontinue specific medication regimes.

Healthcare Professional (HCP) Network

We maintain an extensive network of verified healthcare providers across global markets. This allows for high-level consultative research and rapid data collection from decision-makers in the medical field.

Our HCP data helps businesses:

  • Specialist Consultations: Direct feedback from Oncologists, Cardiologists, and Neurologists.
  • Frontline Insights: Perspectives from specialized Nursing staff and Hospital Administrators.
  • Prescribing Patterns: Understanding the factors that influence a doctor's choice of therapy.
  • Unmet Clinical Needs: Identifying gaps in current medical technology and pharmaceutical offerings.

Market Access & Clinical Feasibility

Navigating global healthcare markets requires precise data on regulatory environments and reimbursement landscapes. Our panel services support your product's lifecycle from clinical trials to commercial launch.

Our core capabilities include:

  • Clinical Trial Recruitment: High-speed identification of eligible participants for specialized trials.
  • Regulatory Feedback: Insights into local compliance and health technology assessment (HTA) requirements.
  • Reimbursement Strategies: Analysis of payer perspectives and insurance coverage trends.
  • Competitive Landscape: Monitoring the adoption and performance of competitor drugs and devices.